ImmunityBio（纳斯达克代码：IBRX）报告季度每股亏损为$(0.09)，优于分析师共识预期的$(0.20)，高出55%。相比去年同期每股亏损$(0.35)，这是一个74.29%的增长。公司报告季度销售额为755万美元，低于分析师共识预期的782万美元，低了3.39%。相比去年同期的13.9万美元，这是一个5.33K%的增长。

以上内容来自Benzinga Earnings专栏，原文如下：

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.20) by 55 percent. This is a 74.29 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $7.55 million which missed the analyst consensus estimate of $7.82 million by 3.39 percent. This is a 5.33K percent increase over sales of $139.00 thousand the same period last year.